Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by EMA
January 08, 2014 at 07:03 AM EST
Bristol-Myers Squibb (NYSE: BMY ) today announced that the European Medicines Agency (EMA) has validated the company's marketing authorization application (MAA) for the use of daclatasvir (DCV),